Paper31311005
How and when to use temozolomide to treat aggressive pituitary tumours.
Whitelaw BC. Endocr Relat Cancer, 2019. Cited by 25 papers, by iCite.
Cite this record
ConductScience Library. How and when to use temozolomide to treat aggressive pituitary tumours. Papers, record 31311005. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/31311005
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents, Alkylating | Major topic |
| Neoplasm Recurrence, Local | Major topic |
| Pituitary Neoplasms | Major topic |
| Temozolomide | Major topic |
| Humans | |
| Prognosis | |
| Time-to-Treatment |
Source PubMed
Cited by21
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 25 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42150200 | Cervical vertebral body metastasis from a gonadotroph pituitary neuroendocrine tumor: illustrative case. | J Neurosurg Case Lessons | 2026 | https://conductscience.org/library/papers/42150200 | PubMed |
| 41894067 | Temozolomide in aggressive and metastatic pituitary tumors: a Brazilian multicenter real-world cohort study. | Pituitary | 2026 | https://conductscience.org/library/papers/41894067 | PubMed |
| 40806825 | Management of Recurrent and Aggressive Non-Functioning Pituitary Adenomas. | J Clin Med | 2025 | https://conductscience.org/library/papers/40806825 | PubMed |
| 40804505 | Consensus on acromegaly therapeutic outcomes: an update. | Nat Rev Endocrinol | 2025 | https://conductscience.org/library/papers/40804505 | PubMed |
| 40362297 | Liquid Biopsy in Pituitary Neuroendocrine Tumors-Potential Biomarkers for Diagnosis, Prognosis, and Therapy. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40362297 | PubMed |
| 40236482 | Exploring the gut microbiome and serum metabolome interplay in non-functioning pituitary neuroendocrine tumors. | Front Microbiol | 2025 | https://conductscience.org/library/papers/40236482 | PubMed |
| 38706730 | Enhancing glioma-specific drug delivery through self-assembly of macrophage membrane and targeted polymer assisted by low-frequency ultrasound irradiation. | Mater Today Bio | 2024 | https://conductscience.org/library/papers/38706730 | PubMed |
| 36856733 | Aggressive Pituitary Tumors and Pituitary Carcinomas: From Pathology to Treatment. | J Clin Endocrinol Metab | 2023 | https://conductscience.org/library/papers/36856733 | PubMed |
| 35865778 | Aggressive prolactinomas responsive to temozolomide treatment: Report of two cases. | Clin Case Rep | 2022 | https://conductscience.org/library/papers/35865778 | PubMed |
| 35368902 | A Retrospective Trail Investigating Temozolomide Neoadjuvant Chemotherapy Combined with Radiotherapy in Low-Grade Pituitary Tumors. | J Oncol | 2022 | https://conductscience.org/library/papers/35368902 | PubMed |
| 34975752 | Early Initiation of Temozolomide Therapy May Improve Response in Aggressive Pituitary Adenomas. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34975752 | PubMed |
| 34934445 | Aggressive prolactinoma (Review). | Exp Ther Med | 2022 | https://conductscience.org/library/papers/34934445 | PubMed |
| 34900530 | Sinomenine ester derivative inhibits glioblastoma by inducing mitochondria-dependent apoptosis and autophagy by PI3K/AKT/mTOR and AMPK/mTOR pathway. | Acta Pharm Sin B | 2021 | https://conductscience.org/library/papers/34900530 | PubMed |
| 34867776 | Treatment of Aggressive Pituitary Adenomas: A Case-Based Narrative Review. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34867776 | PubMed |
| 34840971 | Identification of Hub Gene GRIN1 Correlated with Histological Grade and Prognosis of Glioma by Weighted Gene Coexpression Network Analysis. | Biomed Res Int | 2021 | https://conductscience.org/library/papers/34840971 | PubMed |
| 34493834 | Aggressive pituitary tumours and pituitary carcinomas. | Nat Rev Endocrinol | 2021 | https://conductscience.org/library/papers/34493834 | PubMed |
| 34220707 | Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/34220707 | PubMed |
| 33776913 | Case Report: Temozolomide Treatment of Refractory Prolactinoma Resistant to Dopamine Agonists. | Front Endocrinol (Lausanne) | 2021 | https://conductscience.org/library/papers/33776913 | PubMed |
| 33763363 | Characteristic of Tumor Regrowth After Gamma Knife Radiosurgery and Outcomes of Repeat Gamma Knife Radiosurgery in Nonfunctioning Pituitary Adenomas. | Front Oncol | 2021 | https://conductscience.org/library/papers/33763363 | PubMed |
| 32914330 | Multidisciplinary management of acromegaly: A consensus. | Rev Endocr Metab Disord | 2020 | https://conductscience.org/library/papers/32914330 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MGMT | 4255 | PubTator's text mining | https://conductscience.org/library/genes/4255 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/31311005
GET https://conductscience.org/api/papers/v1/31311005/cited_by?page=2